Merck Says Dr. David Graham's Testimony Unreliable, Inadmissible

NEW ORLEANS - Merck & Co. Inc. is seeking to exclude from the next federal Vioxx MDL trial certain testimony of the FDA's Dr. David Graham that the manufacturer says is irrelevant speculation and would amount to new testimony. In Re: Vioxx Products Liability Litigation, MDL No. 1657 (E.D. La.).

During the week of June 19, counsel for Merck and plaintiff Gerald D. Barnett filed several memoranda concerning the parties' previously filed motions in limine relating to Barnett v. Merck & Co. Inc., No. 06-485.

A hearing on the motions is scheduled for June 28 before Judge Eldon E. Fallon …